The association between the PPARγ2 Pro12Ala polymorphism and nephropathy susceptibility in type 2 diabetes: A meta-analysis based on 9,176 subjects

Diagnostic Pathology

Volumn 8, Issue 1, 2013, Pages 1-7

  Wang, Lei ^a   Teng, Zan ^a   Cai, Shuang ^a   Wang, Difei ^a   Zhao, Xin ^a   Yu, Kai ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Diabetic nephropathy; Meta analysis; Polymorphisms; PPAR 2

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ASIAN; CASE CONTROL STUDY; CAUCASIAN; DIABETIC NEPHROPATHY; ETHNOLOGY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; REVIEW; RISK; RISK FACTOR;

ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; HUMANS; ODDS RATIO; PHENOTYPE; POLYMORPHISM, GENETIC; PPAR GAMMA; RISK FACTORS;

EID: 84882636918     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-8-118     Document Type: Article

References (35)

1. Ayodele OE, Alebiosu CO, Salako BL. Diabetic nephropathy: A review of the natural history, burden, risk factors and treatment. J Natl Med Assoc 2004, 96:1445-1454. 2568593, 15586648.
2. Moczulski DK, Rogus JJ, Antonellis A, Warram JH, Krolewski AS. Major susceptibility locus for nephropathy in type 1 diabetes on chromosome 3q: Results of novel discordant sib-pair analysis. Diabetes 1998, 47:1164-1169. 10.2337/diabetes.47.7.1164, 9648845.
3. Guan Y, Zhang Y, Schneider A, Davis L, Breyer RM, Breyer MD. Peroxisome proliferator-activated receptor-gamma activity is associated with renal microvasculature. Am J Physiol Renal Physiol 2001, 281:F1036-F1046.
4. Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998, 20:284-287. 10.1038/3099, 9806549.
5. Liu L, Zheng T, Wang F, et al. Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients. DiabetesCare 2010, 33:144-149.
6. Argmann CA, Cock TA, Auwerx J. Peroxisome proliferator-activated receptor gamma: The more the merrier?. Eur J Clin Invest 2005, 35:82-92. 10.1111/j.1365-2362.2005.01456.x, 15667578.
7. Desvergne B, Michalik L, Wahli W. Be fit or be sick: Peroxisome proliferator-activated receptors are down the road. Mol Endocrinol 2004, 18:1321-1332. 10.1210/me.2004-0088, 15087471.
8. Caramori ML, Canani LH, Costa LA, Gross JL. The human peroxisome proliferator-activated receptor gamma2 (PPAR-gamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes. Diabetes 2003, 52:3010-3013. 10.2337/diabetes.52.12.3010, 14633865.
9. Herrmann SM, Ringel J, Wang JG, Staessen JA, Brand E. Peroxisome proliferator-activated receptor-gamma2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: The Berlin Diabetes Mellitus (BeDiaM) Study. Diabetes 2002, 51:2653-2657. 10.2337/diabetes.51.8.2653, 12145184.
10. Masugi J, Tamori Y, Mori H, Koike T, Kasuga M. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun 2000, 268:178-182. 10.1006/bbrc.2000.2096, 10652233.
11. Davey SG, Egger M. Meta-analyses of randomized controlled trials. Lancet 1997, 350:1182.
12. Ioannidis JP, Boffetta P, Little J, et al. Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol 2008, 37:120-132. 10.1093/ije/dym159, 17898028.
13. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. Natl Cancer Inst 1959, 22:719-778.
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188. 10.1016/0197-2456(86)90046-2, 3802833.
15. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101. 10.2307/2533446, 7786990.
16. Egger M, Smith DG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634. 10.1136/bmj.315.7109.629, 2127453, 9310563.
17. Mori H, Ikegami H, Kawaguchi Y, et al. The Pro12→Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 2001, 50:891-894. 10.2337/diabetes.50.4.891, 11289058.
18. Wu S. Study on the Relationship of Polymorphism of PPAR-g2 and Type 2 Diabetes and Diabetic Nephropathy 2004, Tianjin: Tianjin Medical University.
19. Maeda A, Gohda T, Funabiki K, Horikoshi S, Tomino Y. Peroxisome proliferator-activated receptor gamma gene polymorphism is associated with serum triglyceride levels and body mass index in Japanese type 2 diabetic patients. J Clin Lab Anal 2004, 18:317-321. 10.1002/jcla.20045, 15543562.
20. Pollex RL, Mamakeesick M, Zinman B, Harris SB, Hegele RA, Hanley AJ. Peroxisome proliferator-activated receptor gamma polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes. J Diabetes Complications 2007, 21:166-171. 10.1016/j.jdiacomp.2006.02.006, 17493550.
21. Erdogan M, Karadeniz M, Eroglu Z, Tezcanli B, Selvi N, Yilmaz C. The relationship of the peroxisome proliferator-activated receptor-gamma 2 exon 2 and exon 6 gene polymorphism in Turkish type 2 diabetic patients with and without nephropathy. Diabetes Res Clin Pract 2007, 78:355-359. 10.1016/j.diabres.2007.06.005, 17681394.
22. Wei F, Wang J, Wang C, Huo X, Xue Y, Bai L. The relationship between the pro12Ala polymorphism in PPAR-g2 gene and diabetic nephropathy in Baotou. Chinese J Diabetes 2008, 16:679-680.
23. Li L, Liu L, Zheng T, Wang N, Wang F. Peroxisome proliferator activated receptor g2 gene P12A polymorphism and type 2 diabetic nephropathy in Han population in Shanghai. J Shanghai Jiaotong Univ 2008, 28:376-379.
24. Wu LS, Hsieh CH, Pei D, Hung YJ, Kuo SW, Lin E. Association and interaction analyses of genetic variants in ADIPOQ, ENPP1, GHSR, PPARgamma and TCF7L2 genes for diabetic nephropathy in a Taiwanese population with type 2 diabetes. Nephrol Dial Transplant 2009, 24:3360-3366. 10.1093/ndt/gfp271, 19506043.
25. De Cosmo S, Motterlini N, Prudente S, et al. BENEDICT Study Group. Impact of the PPAR-gamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICT. Diabetes 2009, 58:2920-2929. 10.2337/db09-0407, 2780880, 19720797.
26. Liu L, Zheng T, Wang F, et al. Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients. Diabetes Care 2010, 33:144-149. 10.2337/dc09-1258, 2797960, 19837787.
27. Lapice E, Pinelli M, Riccardi G, Vaccaro O. Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients: comment on the study by Liu et al. Diabetes Care 2010, 33:e114. 10.2337/dc10-0596, 20668149.
28. Zhu W, Ji Y, Bu L, Yang Q. The correlativity study of peroxisome proliferator activated receptor g2 gene polymorphism with susceptibility of diabetic nephropathy in type 2 diabetes mellitus. J Radio-immunology 2011, 24:296-298.
29. De Cosmo S, Prudente S, Lamacchia O, et al. PPAR{gamma}2 P12A polymorphism and albuminuria in patients with type 2 diabetes: a meta-analysis of case-control studies. Nephrol Dial Transplant 2011, 26:4011-4016. 10.1093/ndt/gfr187, 21493814.
30. Zhang H, Zhu S, Chen J, Tang Y, Hu H, Mohan V, Venkatesan R, Wang J, Chen H. Peroxisome Proliferator-Activated Receptor g Polymorphism Pro12Ala Is Associated With Nephropathy in Type 2 Diabetes. Diabetes Care 2012, 35:1388-1393. 10.2337/dc11-2142, 3357218, 22619290.
31. Fujisawa T, Ikegami H, Kawaguchi Y, et al. Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-con-verting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia 1998, 41:47-53. 10.1007/s001250050865, 9498629.
32. Fei J, Li-Shuai Q, Xi-Zhong S. Association between the methylenetetrahydrofolate reductase C677T polymorphism and hepatocellular carcinoma risk: a meta-analysis. Diagn Pathol 2009, 4:39. 10.1186/1746-1596-4-39, 2788519, 19930673.
33. de Matos L, Adriana Del G, Carolina M, de Lima Farah M, Auro Del G, da Silva Pinhal M. Expression of ck-19, galectin-3 and hbme-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis. Diagn Pathol 2012, 7:97. 10.1186/1746-1596-7-97, 3523001, 22888980.
34. Xue Q, Qiliu P, Aiping Q, Zhiping C, Liwen L, Yan D, Li X, Juanjuan X, Haiwei L, Taijie L, Shan L, Jinmin Z. Association of COMT Val158Met polymorphism and breast cancer risk: an updated meta-analysis. Diagn Pathol 2012, 7:136. 10.1186/1746-1596-7-136, 3543196, 23039364.
35. Liwa Y, Jianqiu C. Association of MHTFR Ala222Val (rs1801133) polymorphism and breast cancer susceptibility: An update meta-analysis based on 51 research studies. Diagn Pathol 2012, 7:171. 10.1186/1746-1596-7-171, 3536596, 23217001.